J Korean Thyroid Assoc.  2012 Nov;5(2):104-108. 10.11106/jkta.2012.5.2.104.

Diagnostic Dilemma of a Follicular Lesions/Neoplasm in Thyroid Fine Needle Aspiration Cytology

• Jung CK

• KMID: 2095098
• DOI: http://doi.org/10.11106/jkta.2012.5.2.104

Abstract

Fine needle aspiration cytology (FNAC) of thyroid nodules is the best screening test for the selection of patients that may require surgical management. However, the diagnosis of follicular neoplasm on FNAC remains a gray area and the main differential diagnosis of follicular neoplasm includes benign (nodular hyperplasia and follicular adenoma) and malignant (follicular carcinoma and follicular variant of papillary carcinoma) lesions. The cytologic diagnosis of follicular neoplasm is based on the high cellularity, microfollicular or trabecular pattern, overlapping follicular cells, and scanty or absent colloid. Histologically, the diagnosis of follicular carcinoma requires the presence of tumor capsular invasion or vascular invasion. In the follicular variant of papillary carcinoma, nuclear features of papillary carcinoma may be subtle and seen in only a small number of cells, and thus may not be readily appreciated. Analyses of BRAF and RAS point mutations and RET/PTC and PAX8/PPARgamma rearrangements have been reported to be a useful ancillary tool for diagnosing thyroid cancer in cytology specimens. The presence of BRAF or RET/PTC mutation is a strong indicator of papillary carcinoma. PAX8/PPARgamma rearrangement is exclusively found in follicular carcinoma. RAS mutations are found in follicular adenoma/carcinoma and follicular variant of papillary carcinoma. Therefore, molecular testing of FNAC samples can improve the accuracy of cytologic diagnosis.

Keyword

Thyroid neoplasm; Fine-needle aspiration; Differential diagnosis; Molecular diagnostic testing

MeSH Terms

Biopsy, Fine-Needle
Carcinoma, Papillary
Colloids
Diagnosis, Differential
Humans
Hyperplasia
Mass Screening
Molecular Diagnostic Techniques
Point Mutation
Thyroid Gland
Thyroid Neoplasms
Thyroid Nodule
Colloids

Reference

1. Yi KH, Park YJ, Koong SS, Kim JH, Na DG, Ryu JS, et al. Revised Korean Thyroid Association Management Guidelines for patients with thyroid nodules and thyroid cancer. Endocrinol Metab. 2010. 25(4):270–297.

2. Ferraz C, Eszlinger M, Paschke R. Current state and future perspective of molecular diagnosis of fine-needle aspiration biopsy of thyroid nodules. J Clin Endocrinol Metab. 2011. 96(7):2016–2026.

3. Lee K, Jung CK, Lee KY, Bae JS, Lim DJ, Jung SL. Application of bethesda system for reporting thyroid aspiration cytology. Korean J Pathol. 2010. 44(5):521–527.

4. Monzani F, Caraccio N, Iacconi P, Faviana P, Dardano A, Basolo F, et al. Prevalence of cancer in follicular thyroid nodules: is there still a role for intraoperative frozen section analysis? Thyroid. 2003. 13(4):389–394.

5. Gharib H, Papini E, Paschke R, Duick DS, Valcavi R, Hegedus L, et al. American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and EuropeanThyroid Association Medical Guidelines for Clinical Practice for the Diagnosis and Management of Thyroid Nodules. Endocr Pract. 2010. 16:Suppl 1. 1–43.

6. Kapur U, Wojcik EM. Follicular neoplasm of the thyroid--vanishing cytologic diagnosis? Diagn Cytopathol. 2007. 35(8):525–528.

7. Piana S, Frasoldati A, Ferrari M, Valcavi R, Froio E, Barbieri V, et al. Is a five-category reporting scheme for thyroid fine needle aspiration cytology accurate? Experience of over 18,000 FNAs reported at the same institution during 1998-2007. Cytopathology. 2011. 22(3):164–173.

8. Henry MR, DeMay RM, Berezowski K. Ali SZ, Cibas ES, editors. Follicular neoplasm/suspicious for a follicular neoplasm. The Bethesda system for reporting thyroid cytopathology. 2010. New York, NY: Springer;51–58.

9. Sobrinho-Simoes M, Asa SL, Kroll TG, Nikiforov YE, DeLellis RA, Farid P, et al. DeLellis RA, Lloyd RV, Heitz PU, Eng C, editors. Follicular carcinoma. World Health Organization classification of tumours. Pathology and genetics: Tumours of endocrine organs. 2004. 2nd ed. Lyon, France: IARC Press;67–76.

10. Paunovic I, Isic T, Havelka M, Tatic S, Cvejic D, Savin S. Combined immunohistochemistry for thyroid peroxidase, galectin-3, CK19 and HBME-1 in differential diagnosis of thyroid tumors. APMIS. 2012. 120(5):368–379.

11. Nikiforov YE, Nikiforova MN. Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol. 2011. 7(10):569–580.

12. Jung CK, Im SY, Kang YJ, Lee H, Jung ES, Kang CS, et al. Mutational patterns and novel mutations of the BRAF gene in a large cohort of Korean patients with papillary thyroid carcinoma. Thyroid. 2012. 22(8):791–797.

13. Eszlinger M, Paschke R. Molecular fine-needle aspiration biopsy diagnosis of thyroid nodules by tumor specific mutations and gene expression patterns. Mol Cell Endocrinol. 2010. 322(1-2):29–37.

14. Kim SW, Lee JI, Kim JW, Ki CS, Oh YL, Choi YL, et al. BRAFV600E mutation analysis in fine-needle aspiration cytology specimens for evaluation of thyroid nodule: a large series in a BRAFV600E-prevalent population. J Clin Endocrinol Metab. 2010. 95(8):3693–3700.

15. Nam SY, Han BK, Ko EY, Kang SS, Hahn SY, Hwang JY, et al. BRAF V600E mutation analysis of thyroid nodules needle aspirates in relation to their ultrasongraphic classification: a potential guide for selection of samples for molecular analysis. Thyroid. 2010. 20(3):273–279.

16. Yeo MK, Liang ZL, Oh T, Moon Y, An S, Kim MK, et al. Pyrosequencing cut-off value identifying BRAFV600E mutation in fine needle aspiration samples of thyroid nodules. Clin Endocrinol (Oxf). 2011. 75(4):555–560.

17. Nikiforov YE, Ohori NP, Hodak SP, Carty SE, LeBeau SO, Ferris RL, et al. Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab. 2011. 96(11):3390–3397.

18. Lee ST, Kim SW, Ki CS, Jang JH, Shin JH, Oh YL, et al. Clinical implication of highly sensitive detection of the BRAF V600E mutation in fine-needle aspirations of thyroid nodules: a comparative analysis of three molecular assays in 4585 consecutive cases in a BRAF V600E mutation-prevalent area. J Clin Endocrinol Metab. 2012. 97(7):2299–2306.

20. Nikiforov YE. Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med. 2011. 135(5):569–577.

21. Nikiforov YE, Ohori NP. Nikiforov YE, Biddinger PW, Thompson LDR, editors. Follicular carcinoma. Diagnostic pathology and molecular genetics of the thyroid. 2009. Baltimore, Philadelphia: Lipppincott Williams & Wilkins;132–159.

22. Garcia-Rostan G, Zhao H, Camp RL, Pollan M, Herrero A, Pardo J, et al. ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. J Clin Oncol. 2003. 21(17):3226–3235.

23. Manenti G, Pilotti S, Re FC, Della Porta G, Pierotti MA. Selective activation of ras oncogenes in follicular and undifferentiated thyroid carcinomas. Eur J Cancer. 1994. 30A(7):987–993.

24. Basolo F, Pisaturo F, Pollina LE, Fontanini G, Elisei R, Molinaro E, et al. N-ras mutation in poorly differentiated thyroid carcinomas: correlation with bone metastases and inverse correlation to thyroglobulin expression. Thyroid. 2000. 10(1):19–23.

25. Marotta V, Guerra A, Sapio MR, Vitale M. RET/PTC rearrangement in benign and malignant thyroid diseases: a clinical standpoint. Eur J Endocrinol. 2011. 165(4):499–507.

26. Chudova D, Wilde JI, Wang ET, Wang H, Rabbee N, Egidio CM, et al. Molecular classification of thyroid nodules using high-dimensionality genomic data. J Clin Endocrinol Metab. 2010. 95(12):5296–5304.

27. Kim SK, Hwang TS, Yoo YB, Han HS, Kim DL, Song KH, et al. Surgical results of thyroid nodules according to a management guideline based on the BRAF(V600E) mutation status. J Clin Endocrinol Metab. 2011. 96(3):658–664.

28. Chung KW, Yang SK, Lee GK, Kim EY, Kwon S, Lee SH, et al. Detection of BRAFV600E mutation on fine needle aspiration specimens of thyroid nodule refines cyto-pathology diagnosis, especially in BRAF600E mutation-prevalent area. Clin Endocrinol (Oxf). 2006. 65(5):660–666.